? Flow Cytometry and Cell Sorting Facility The Flow Cytometry and Cell Sorting Facility at the Abramson Cancer Center (ACC) has been continuously funded by the NCI Cancer Center Support Grant since 1981. The Facility is recognized as a worldwide leader in cytometry and cytomics and is one of the largest and most comprehensive academic flow cytometry Shared Resources in North America. A full range of cytomic services is offered including analytical cytometry of up to 30 parameters, detection and analysis of extracellular vesicles, basic and ultra-rare cell sorting, single cell multiomic analysis, computational cytomic data analysis, permanent data archive, expert consultation, and a comprehensive education program. Jonni Moore, PhD, Professor of Pathology and Laboratory Medicine with a doctorate in immunology, has directed the Facility since 1990. She is the 2020-2022 President of the International Society for the Advancement of Cytometry (ISAC), a noted expert in deep phenotyping and extracellular vesicle cytometry, and a highly respected expert in Shared Resource operation. The leadership team also includes Thomas Williams, BS, SCYM(ASCP)CM, the new Technical Director of Operations and Client Services, with more than 30 years of Shared Resource leadership. Derek Jones, PhD, SCYM(ASCP)CM, the new Director for Research and Development, is an immunology PhD recently selected as an ISAC Shared Resource Emerging Leader. This team is supported by eight other full time-equivalent staff with an average of 15 years' experience. With cutting-edge cytomic technology and instrumentation, and extensive expertise, ACC members have access to complete experimental design and technical support, data analysis and interpretation. During the current period, the Facility continued to experience significant growth, reflecting the recent expanded interest in cell-based analysis in cancer research. ACC members accounted for 113 of 255 researchers (44%) who used the Facility during this reporting period (July 1, 2018 through June 30, 2019). The Facility supported multiple high impact studies, including the elucidation of immunological and clinical response to PD-1 blockade leading to novel mechanistic insights and provoking new clinical trials (Huang et al., Nat Med, 2019; Huang et al., Nature, 2017). The success of the Facility can be attributed to several factors: hiring and retaining highly qualified staff (by creating a new career track for Shared Resource laboratory staff); constant evaluation and subsequent purchase of the most cutting-edge instrumentation; the use of satellite facilities, with 24/7 access, purposefully located near major user groups; implementation of a highly effective training program; major operational IT support (on-line scheduling, central archiving of data, site-licensing software to investigators to perform data analysis in their laboratories). This results in a highly cost-effective operation offering ACC investigators access to world class expertise in cytomics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-45
Application #
10088761
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-15
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7
Raghunathan, Nirupa Jaya; Korenstein, Deborah; Li, Qing S et al. (2018) Determinants of mobile technology use and smartphone application interest in cancer patients. Cancer Med 7:5812-5819
Hordeaux, Juliette; Wang, Qiang; Katz, Nathan et al. (2018) The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Mol Ther 26:664-668
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:
Torre, Eduardo; Dueck, Hannah; Shaffer, Sydney et al. (2018) Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH. Cell Syst 6:171-179.e5
Vonderheide, Robert H (2018) The Immune Revolution: A Case for Priming, Not Checkpoint. Cancer Cell 33:563-569
Romero, Sally A D; Jones, Lee; Bauml, Joshua M et al. (2018) The association between fatigue and pain symptoms and decreased physical activity after cancer. Support Care Cancer 26:3423-3430
Safo, Sandra E; Li, Shuzhao; Long, Qi (2018) Integrative analysis of transcriptomic and metabolomic data via sparse canonical correlation analysis with incorporation of biological information. Biometrics 74:300-312
Kall, Stefanie L; Delikatny, Edward J; Lavie, Arnon (2018) Identification of a Unique Inhibitor-Binding Site on Choline Kinase ?. Biochemistry 57:1316-1325

Showing the most recent 10 out of 1047 publications